Watchlist Price Alert

Alnylam Pharmaceuticals I... (ALNY)

NASDAQ: ALNY · Real-Time Price · USD

259.20

4.07 (1.60%)

At close: May 02, 2025, 3:59 PM

259.39

0.07%

After-hours: May 02, 2025, 04:05 PM EDT

1.60% (1D)

Bid	247.89
Market Cap	33.72B
Revenue (ttm)	2.35B
Net Income (ttm)	-269.7M
EPS (ttm)	-2.09
PE Ratio (ttm)	-124.02
Forward PE	171.22
Analyst	Buy

Ask	260
Volume	422,578
Avg. Volume (20D)	929,937
Open	258.11
Previous Close	255.13
Day's Range	257.11 - 263.12
52-Week Range	144.73 - 304.39
Beta	0.30

About ALNY

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases. Its marketed products include ONPATTRO (patisiran), a lipid complex injection f...

[Read more]

Industry Biotechnology

Sector Healthcare

IPO Date Jun 1, 2004

Employees 2,230

Stock Exchange NASDAQ

Ticker Symbol ALNY

Website https://www.alnylam.com

Full Company Profile

Analyst Forecast

According to 24 analyst ratings, the average rating for ALNY stock is "Buy." The 12-month stock price forecast is $326.5, which is an increase of 25.96% from the latest price.

Stock Forecasts

Earnings Surprise

Alnylam Pharmaceuticals has released their quartely earnings on May 1, 2025:

Revenue of $594.19M exceeds estimates by $8.37M, with 20.20% YoY growth.

EPS of -0.01 exceeds estimates by 1.02, with 93.75% YoY growth.

Why Price Moved

1 month ago

+2.6%

Alnylam Pharmaceuticals shares are trading higher ... Unlock content with Pro Subscription

1 month ago

+11.75%

Alnylam Pharmaceuticals shares are trading higher after the company secured FDA approval pf sNDA for its RNAi therapeutic, AMVUTTRA ,for treatment of ATTR-CM in adults.

News

2 days ago · zacks.com

Alnylam Q1 Earnings Beat Estimates, Product Revenues Rise Y/Y

ALNY reports better-than-expected first-quarter results as both earnings and revenues beat estimates, driven by higher product sales.

3 days ago · seekingalpha.com

Alnylam Pharmaceuticals, Inc. (ALNY) Q1 2025 Earnings Call Transcript

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY ) Q1 2025 Earnings Conference Call May 1, 2025 8:30 AM ET Company Participants Christine Lindenboom – Chief Corporate Communications Officer Yvonne Greenstre...

3 days ago · zacks.com

Compared to Estimates, Alnylam (ALNY) Q1 Earnings: A Look at Key Metrics

While the top- and bottom-line numbers for Alnylam (ALNY) give a sense of how the business performed in the quarter ended March 2025, it could be worth looking at how some of its key metrics compare t...

2 days ago · zacks.com

Alnylam Pharmaceuticals (ALNY) Reports Q1 Loss, Tops Revenue Estimates

Alnylam Pharmaceuticals (ALNY) came out with a quarterly loss of $0.01 per share versus the Zacks Consensus Estimate of a loss of $0.56. This compares to loss of $0.16 per share a year ago.

4 days ago · zacks.com

Seeking Clues to Alnylam (ALNY) Q1 Earnings? A Peek Into Wall Street Projections for Key Metrics

Evaluate the expected performance of Alnylam (ALNY) for the quarter ended March 2025, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics fo...

6 days ago · businesswire.com

Alnylam Receives Positive CHMP Opinion for Vutrisiran for the Treatment of ATTR Amyloidosis with Cardiomyopathy

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNA interference (RNAi) therapeutics company, today announced that the Committee for Medicinal Products for...

1 week ago · zacks.com

Earnings Preview: Alnylam Pharmaceuticals (ALNY) Q1 Earnings Expected to Decline

Alnylam (ALNY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 weeks ago · businesswire.com

Alnylam to Webcast Conference Call Discussing First Quarter 2025 Financial Results

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the first quarter endi...

3 weeks ago · zacks.com

Alnylam (ALNY) Moves 8.5% Higher: Will This Strength Last?

Alnylam (ALNY) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in ...

1 month ago · businesswire.com

Alnylam to Webcast Presentation at Needham 24th Annual Virtual Healthcare Conference

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the Needham 2...

Load More News